Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Investor Presentation (December 2024)
19 slides from Avita Medical's investor presentation, Dec 4, 2024
Slide 1: Investor Presentation December 2024
For personal use only Investor Presentation December 2024
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results, perform
Slide 3: Who We Are
Who We Are Commercial-stage regenerative For personal use only Deliver innovative wound closure medicine company transforming OUR MISSION solutions, enabling transformative patient the standard of care in wound outcomes. care management and skin Become the leading global regenerative restoration wit
Slide 4: Our Leadership
Our Leadership For personal use only J I M CO R B E T T DAV I D O ’ TO O L E N I CO L E K E L S EY D E B B I E GAR N E R RO B I N VAN D E N B U RGH Chief Executive Officer* Chief Financial Officer* Chief Legal and Compliance SVP, Global Marketing & Strategy SVP, U.S. Commercial Sales 30+ Years of Ex
Slide 5: RECELL at the Core of a Comprehensive Portfolio
BUILDING A BROAD-BASED WOUND CARE COMPANY RECELL at the Core of a Comprehensive Portfolio Adjacent Markets of Burn And Full-Thickness Skin Defect Wound Care For personal use only Flagship Device Wound Depth Wound Bed Wound Bed Dermal Dressings Wound Scar Assessment Preparation / Hemostasis Replaceme
Slide 6: Defining the Standard in Wound Care & Skin Regeneration
Defining the Standard in Wound Care & Skin Regeneration Two-Stage Procedure For personal use only Wound Bed Epidermal Wound Site Dermal Matrix Temporizing Replacement Coverage Coming Soon in 2025 Revolutionary biosynthetic Collagen-based dermal First-in-class device Revolutionary transparent matrix
Slide 7: RECELL Platform
RECELL Platform 2024 2025 For personal use only R EC E L L GO • Two components: multi-use, AC-powered RECELL GO Processing Device (“RPD”) and a RECELL GO UP TO ~10% TOTAL BODY SURFACE UP TO ~2.5% TOTAL BODY Preparation Kit (“RPK”) AREA SURFACE AREA • RPK includes: single-use RECELL GO Cartridge, • L
Slide 8: RECELL GO: Optimizing Patient Care and Accelerating Recovery
RECELL GO: OPTIMIZING PATIENT CARE AND ACCELERATING RECOVERY Reduces OR Time and Anesthesia, and Streamlines Workflow Multiple devices Enhanced Effectively For personal use only maximize operating features reduce treats large wounds room efficiency training burden Burn injury between Burn injury bet
Slide 9: PermeaDerm: Next Generation Skin Substitute
PermeaDerm: Next Generation Skin Substitute1,2 DUAL-LAYER BIOSYNTHETIC WOUND MATRIX 1 For personal use only Dressing optimized for protection and moisture management Outer Layer: Slitted 2D Silicone Epidermal Analogue Transparency reduces wound site disruption Protects wound from trauma Bacterial ba
Slide 10: Cohealyx: A Unique Collagen Dermal Matrix
Cohealyx: A Unique Collagen Dermal Matrix AVITA MEDICAL-BRANDED: For personal use only • Collagen-based dermal matrix promotes revascularization and provides cellular structure to guide tissue regeneration PRECLINICAL PORCINE STUDIES: • Demonstrates reduced time to be graft-ready • Faster integratio
Slide 11: Preliminary Pre-Clinical Wound Bed Preparation & Graft Take
Preliminary Pre-Clinical Wound Bed Preparation & Graft Take¹ Competitor A Competitor B 1 PRE-CLINICAL SKIN GRAFT TAKE For personal use only 100 0 Day Percent Skin Graft Take (Day 7) 90 * Cohealyx² (n=8) 7 Days 80 Competitor A (n=10) 70 Competitor B (n=5) Prior to Skin Grafting 7 Days 60 50 Post-Skin
Slide 12: Avita Medical Portfolio: Product Compatibility and Revenue Potential
AVITA MEDICAL PORTFOLIO Product Compatibility and Revenue Potential For personal use only FULL-THICKNESS WOUND IN TWO-STAGE PROCEDURE Our TAM expands from $450 million to $1.5 billion in burn market alone Potential Revenue Per Patient3 PermeaDerm $2,000 – $4,000 Dressing RECELL1 $6,500 – $13,000 Epi
Slide 13: RECELL U.S. Market Sizing for Burn and Full-Thickness Skin Defects
RECELL U.S. Market Sizing for Burn and Full-Thickness Skin Defects Applying our product compatibility and revenue model to the full-thickness market expands For personal use only our TAM by greater than $2 billion TOTAL MARKET OPPORTUNITY OF RECELL—ELIGIBLE PROCEDURES ~400,000 annual full-thickness
Slide 14: Summary Future Outlook and Vision
For personal use only Summary Future Outlook and Vision P 14
Slide 15: Global Commercialization Strategy for RECELL
Global Commercialization Strategy for RECELL FOCUSED MARKET For personal use only • Australia • European Union • Japan STRATEGY • Plan to expand exclusively through third-party distribution partners DISTRIBUTION PARTNERS • We have secured agreements in 16 countries: • Australia, Germany, Austria, Sw
Slide 16: Looking Ahead: Q4 2024 Priorities
Looking Ahead: Q4 2024 Priorities > SA L ES E X ECU T I O N • Expand into trauma centers with full-thickness skin defect indication For personal use only • Drive RECELL GO conversions to 95+% of our revenue base by year end P RO D U CT P O RT FO L I O E X PAN S I O N FDA approvals: > • Expect 510(k)
Slide 17: Financial Update
Financial Update Q3 2024 FINANCIAL RESULTS 2024 FINANCIAL GUIDANCE For personal use only Commercial revenue: Commercial revenue: • $19.5 million, an increase of ~44% year-over-year • Q4 2024: expect $22.3 to $24.3 million, representing ~58% to 72% growth year-over-year Gross profit margin: • FY 2024
Slide 18: Quarterly Commercial Revenue
Quarterly Commercial Revenue STRONG COMMERCIAL GROWTH use only $25,000 $23,3001 Revenue (in thousands) $20,000 $19,482 personal $15,133 $15,000 $13,546 $14,097 $11,687 $11,069 $10,458 $10,000 $9,364 40% 42% 50% 29% 44% 65%1 Year-Over-Year Growth Commercial 51% 6% For $5,000 $0 Ryan Zimmerman, BTIG
Slide 19: For personal use only
For personal use only
AVITA Medical — Investor Presentation (December 2024) on 6ix